Equities Analysts Issue Forecasts for Surmodics Q2 Earnings

Surmodics, Inc. (NASDAQ:SRDX) – Stock analysts at Barrington Research dropped their Q2 2026 EPS estimates for Surmodics in a note issued to investors on Thursday, May 1st. Barrington Research analyst M. Petusky now forecasts that the company will post earnings per share of $0.01 for the quarter, down from their previous estimate of $0.03. The consensus estimate for Surmodics’ current full-year earnings is $0.20 per share. Barrington Research also issued estimates for Surmodics’ Q3 2026 earnings at $0.01 EPS, Q4 2026 earnings at $0.07 EPS and FY2027 earnings at $0.28 EPS.

Surmodics (NASDAQ:SRDX) last announced its earnings results on Wednesday, April 30th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.07). The business had revenue of $28.09 million for the quarter, compared to analysts’ expectations of $32.23 million. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%.

A number of other analysts have also issued reports on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a research note on Wednesday. Lake Street Capital raised shares of Surmodics from a “hold” rating to a “buy” rating and set a $43.00 target price for the company in a report on Friday, March 7th. Finally, StockNews.com started coverage on shares of Surmodics in a research report on Monday, February 3rd. They issued a “hold” rating for the company. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Surmodics currently has an average rating of “Hold” and a consensus target price of $43.00.

Surmodics Trading Down 0.8 %

SRDX stock opened at $27.64 on Friday. Surmodics has a 12-month low of $26.00 and a 12-month high of $42.44. The business’s 50-day moving average is $29.43 and its 200 day moving average is $34.89. The company has a current ratio of 5.45, a quick ratio of 4.29 and a debt-to-equity ratio of 0.26. The stock has a market cap of $395.14 million, a price-to-earnings ratio of -27.37 and a beta of 1.30.

Hedge Funds Weigh In On Surmodics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SRDX. Principal Financial Group Inc. raised its holdings in shares of Surmodics by 1.8% during the 1st quarter. Principal Financial Group Inc. now owns 36,699 shares of the company’s stock worth $1,120,000 after acquiring an additional 638 shares during the period. Salem Investment Counselors Inc. increased its position in Surmodics by 1.1% during the first quarter. Salem Investment Counselors Inc. now owns 114,950 shares of the company’s stock worth $3,509,000 after purchasing an additional 1,200 shares during the last quarter. California State Teachers Retirement System raised its stake in Surmodics by 5,005.0% during the fourth quarter. California State Teachers Retirement System now owns 50,999 shares of the company’s stock worth $2,020,000 after purchasing an additional 50,000 shares during the period. Phocas Financial Corp. boosted its holdings in Surmodics by 17.6% in the 4th quarter. Phocas Financial Corp. now owns 103,994 shares of the company’s stock valued at $4,118,000 after purchasing an additional 15,534 shares during the last quarter. Finally, Alpine Global Management LLC purchased a new stake in shares of Surmodics in the 4th quarter valued at approximately $1,980,000. Institutional investors and hedge funds own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).